within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02C_OtherGynecologicals.G02CB01_Bromocriptine;

model Bromocriptine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.065,
    Cl = 6.36e-05,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.1776,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0024333333333333334,
    Tlag = 600,
    Vdp = 1.504,
    k12 = 0.00013875,
    k21 = 0.00013875);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bromocriptine</td></tr><tr><td>ATC code:</td><td>G02CB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>177.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>228.96</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bromocriptine is a dopamine receptor agonist derived from ergot alkaloids. It is used primarily in the treatment of Parkinson's disease, hyperprolactinemia, acromegaly, and type 2 diabetes mellitus. It is an approved medication and is still in clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on healthy adult volunteers (both sexes), single oral dose administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G02CB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bromocriptine;
